NSCLC_treatment_sequencing_survey
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC More than one-third of physicians report not having sufficient information to decide on how to sequence specific targeted lung cancer treatmentsSurvey findings presented today as a late-breaking abstract at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Canada Health | Cancer | Cancer & Oncology | Conferences | Lung Cancer | Non-Small Cell Lung Cancer | Research